Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes.

BACKGROUND

The inflammasome plays an essential role in lower risk MDS and immune subversion, with the up-regulation of immune checkpoint molecules in the progression to higher-risk disease. In this study, we explored the utility of immune-related biomarkers for the diagnosis and prognosis of MDS.

METHODS

We performed an exploratory, case-control study with 20 randomly selected MDS patients and nine controls with non-inflammatory ( = 3) and inflammatory conditions ( = 6). Patients were stratified in groups of lower ( = 10) and higher risk ( = 10) using IPSS-R. For the exploration of inflammasome and immune checkpoint activities, the expression of caspase-1 (Casp1), programmed cell death protein 1 (PD-1) and its ligand (PD-L1) were assessed in bone marrow samples using immunohistochemistry.

RESULTS

In multivariate analysis, we observed significant differences for Casp1 but not PD1/PD-L1 expression in our four conditions ( = 0.003). We found a discordant co-expression of Casp1/PD-L1 in MDS (rho = -0.41, = 0.07) compared with a concordant co-expression in controls (rho = 0.64, = 0.06). Neutrophil counts correlated directly with Casp1 (rho = 0.57, 0.009) but inversely with PD-L1 expression (rho = -0.58, = 0.007).

CONCLUSION

We identified characteristic discordant co-expression patterns in lower- (Casp1/PD-L1) and higher-risk MDS (Casp1/PD-L1), contrasting with concordant patterns in the non-inflammatory (Casp1/PD-L1) and inflammatory conditions (Casp1/PD-L1). Further validation is warranted in larger, prospective studies.